Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures to assess blood flow to the muscle of the heart; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical used in the manufacture of sources for the calibration and maintenance of single-photon emission computed tomography imaging cameras. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment follow-up of neuroendocrine tumors. The company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone978-671-8001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$343.37 million
Profitability
Miscellaneous
Employees488
Next Earnings Date4/29/2019 (Confirmed)
OptionableOptionable
Lantheus (NASDAQ:LNTH) Frequently Asked Questions
What is Lantheus' stock symbol?
Lantheus trades on the NASDAQ under the ticker symbol "LNTH."
How were Lantheus' earnings last quarter?
Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings data on Tuesday, February, 19th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.09. The medical equipment provider earned $86.27 million during the quarter, compared to analyst estimates of $83.93 million. Lantheus had a net margin of 11.80% and a return on equity of 73.07%. Lantheus's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.47 EPS. View Lantheus' Earnings History.
When is Lantheus' next earnings date?
What guidance has Lantheus issued on next quarter's earnings?
Lantheus updated its FY19 earnings guidance on Tuesday, February, 19th. The company provided earnings per share (EPS) guidance of $1.14-1.17 for the period, compared to the Thomson Reuters consensus estimate of $0.96. The company issued revenue guidance of $358-363 million, compared to the consensus revenue estimate of $361.50 million.Lantheus also updated its FY 2019 guidance to $1.14-1.17 EPS.
What price target have analysts set for LNTH?
2 brokers have issued 12 month target prices for Lantheus' shares. Their predictions range from $20.00 to $21.00. On average, they expect Lantheus' share price to reach $20.50 in the next year. This suggests that the stock has a possible downside of 15.0%. View Analyst Price Targets for Lantheus.
What is the consensus analysts' recommendation for Lantheus?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.
Has Lantheus been receiving favorable news coverage?
Media headlines about LNTH stock have been trending negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Lantheus earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near term.
Who are some of Lantheus' key competitors?
Some companies that are related to Lantheus include Immunomedics (IMMU), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and ImmuCell (ICCC).
What other stocks do shareholders of Lantheus own?
Who are Lantheus' key executives?
Lantheus' management team includes the folowing people:
- Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
- Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
- Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
- Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
- Mr. John J. Bolla, Sr. VP of Technical Operations (Age 49)
When did Lantheus IPO?
(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.
Who are Lantheus' major shareholders?
Lantheus' stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (1.94%), OmniStar Financial Group Inc. (0.03%), Nkcfo LLC (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Lantheus stock include A Frederick Robertson, Avista Capital Partners Gp, Ll, Brian A Markison, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Timothy G Healey. View Institutional Ownership Trends for Lantheus.
Which major investors are selling Lantheus stock?
LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, Julie Mchugh, Mary Anne Heino and Michael P Duffy. View Insider Buying and Selling for Lantheus.
Which major investors are buying Lantheus stock?
How do I buy shares of Lantheus?
Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lantheus' stock price today?
One share of LNTH stock can currently be purchased for approximately $24.12.
How big of a company is Lantheus?
Lantheus has a market capitalization of $929.78 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.
What is Lantheus' official website?
How can I contact Lantheus?
Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]
MarketBeat Community Rating for Lantheus (NASDAQ LNTH)
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
